U.K. researchers report big immunotherapy flop for long-sought cancer vaccine

Ryan McBride Not all the immunotherapies have impressed at ASCO in Chicago. A large Phase III study of the immunotherapy GV1001 showed an insignificant difference in overall survival ...

Synta surges on positive lung cancer data for ganetespib

John Carroll Shares of Synta climbed more than 10% today after news spread that its drug ganetespib spurred a 32% increase in survival for advanced lung cancer patients. FierceBiotech ...

Clovis soars on upbeat signs of efficacy for targeted cancer drugs

John Carroll FierceBiotech News

Study: Avastin Doesn’t Lengthen Survival in Some Brain Cancer Patients

barbara.lempert Drug Doesn’t Lengthen Survival in Some Brain Cancer Patients The drug Avastin combined with chemotherapy and radiation failed to prolong survival in ...

Avastin improves outcomes for cervical cancer but flunks first-line brain cancer test

John Carroll FiercePharma News

Bayer’s Nexavar hits the brakes on thyroid cancer progression

John Carroll FierceBiotech News

Big Ten Universities Form Big Ten Cancer Research Consortium

barbara.lempert Big Ten universities form Big Ten Cancer Research Consortium INDIANAPOLIS, May 31, 2013 /PRNewswire-USNewswire/ — In athletics, the Big Ten universities compete ...

New Mobile App Assists Oncologists In Navigating Ever-Evolving Sea Of Cancer Information

barbara.lempert Lilly Oncology partners with MDLinx to make new research easily accessible INDIANAPOLIS, May 31, 2013 /PRNewswire/ — Recent advancements in cancer research ...

Lung cancer spotlighted as prime target for new immunotherapies

Ryan McBride Even before the ASCO meeting opened today, the industry has been abuzz about the breakthrough potential of new immunotherapies to restore immune attacks on cancers. FierceBiotech ...

Rebellious FDA Reviewer Insists ARB Heart Drugs Have Cancer Risk

esilverman Yet another instance of an FDA medical reviewer clashing with agency supervisors is playing out over a group of drugs called angiotension receptor blockers, which ...

Epizyme scores latest biotech IPO victory to advance cancer pipeline

Ryan McBride The Cambridge, MA-based developer of targeted cancer drugs sold about 5.9 million shares for $ 15 per share, hitting the high end of its proposed $ 13-$ 15 per share ...

New European Phase II Trial to Test Immunovaccine’s DPX-Survivac In Brain Cancer Patients

barbara.lempert –    IMV’s vaccine targets survivin peptides present on most Glioblastoma (Brain Cancer) cells –    Patients to receive DPX-Survivac in combination ...
Page 20 of 23« First...10...1819202122...Last »
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS